Skip to content

Reduction of Risk for Cardiovascular Diseases

Reducing the Risk of Cardiovascular Diseases in Community-dwelling Adults: an Ambispective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05431400
Enrollment
20000
Registered
2022-06-24
Start date
2020-01-01
Completion date
2025-12-31
Last updated
2022-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Keywords

Cardiovascular Diseases, Prediction model, Community

Brief summary

To establish and evaluate a new prediction model for assessing cardiovascular disease risk in community-dwelling adults.

Detailed description

This is an ambispective, observational cohort study. In the retrospective part, we will enroll residents from Guangzhou or Foshan who participated in the annual health checks provided by the Chinese National Basic Public Health Service project between January 2015 and December 2019. The demographic characteristics, anthropometric measurements, laboratory assays, medical history, living habits, and medications will be collected through personal electronic health records obtained from the regional chronic disease management platform. In the prospective part, residents who participated in the annual health checks provided by the Chinese National Basic Public Health Service project after January 2020 will be enrolled. In addition to the data collected in the retrospective part, blood, urine and fecal samples and lifestyle questionnaires will be collected for further analysis. All participants will be followed-up till December 2025. A new prediction model for assessing cardiovascular disease risk will be established and evaluated.

Interventions

None listed

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Meet at least one of the following conditions: 1. Age ≥ 65 years; 2. Diabetes mellitus; 3. Hypertension;

Exclusion criteria

* Refuse to provide informed consent;

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiovascular events5 yearsMajor adverse cardiovascular events include all-cause mortality, acute myocardial infarction, coronary heart disease, heart failure and stroke.

Secondary

MeasureTime frameDescription
All-cause mortality5 yearsDefined as any death after enrollment.
Cognitive dysfunction5 yearsDefined as Montreal Cognitive Assessment (MoCA) Score \< 26 points.
Atherosclerotic cardiovascular events5 yearsAtherosclerotic cardiovascular events include acute myocardial infarction, coronary heart disease, heart failure and fatal and non-fatal stroke.
Renal replacement therapy and/or death due to acute renal failure5 years
Incident atrial fibrillation5 yearsAtrial fibrillation is diagnosed according to the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation.
Renal functional deterioration5 yearsEvaluated through change in estimated glomerular filtration rate.

Countries

China

Contacts

Primary ContactJiancheng Xiu, MD
xiujch@163.com+86-020-61648319

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026